Genscript Biotech Corporation (G51) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genscript Biotech Corporation (G51) has a cash flow conversion efficiency ratio of -0.045x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-93.58 Million ≈ $-109.41 Million USD) by net assets (€2.09 Billion ≈ $2.44 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Genscript Biotech Corporation to measure how many days the company can operate on defensive assets alone.
Genscript Biotech Corporation - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Genscript Biotech Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genscript Biotech Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genscript Biotech Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nuvama Wealth
NSE:NUVAMA
|
N/A |
|
Dolby Laboratories
NYSE:DLB
|
0.134x |
|
Anhui Jingcheng Copper Share Co Ltd
SHE:002171
|
-0.009x |
|
Sinoma International Engineering Co Ltd
SHG:600970
|
0.096x |
|
Hyundai Steel
KO:004020
|
0.027x |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
0.066x |
|
Fujian Longking Co Ltd
SHG:600388
|
0.076x |
|
Stella-Jones Inc.
TO:SJ
|
0.022x |
Annual Cash Flow Conversion Efficiency for Genscript Biotech Corporation (2016–2025)
The table below shows the annual cash flow conversion efficiency of Genscript Biotech Corporation from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Genscript Biotech Corporation worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.96 Billion ≈ $4.64 Billion |
€325.52 Million ≈ $380.57 Million |
0.082x | +369.25% |
| 2024-12-31 | €4.32 Billion ≈ $5.05 Billion |
€75.65 Million ≈ $88.44 Million |
0.017x | +112.47% |
| 2023-12-31 | €2.04 Billion ≈ $2.39 Billion |
€-286.91 Million ≈ $-335.43 Million |
-0.140x | -58.98% |
| 2022-12-31 | €1.36 Billion ≈ $1.59 Billion |
€-120.29 Million ≈ $-140.63 Million |
-0.088x | +29.47% |
| 2021-12-31 | €1.09 Billion ≈ $1.28 Billion |
€-136.79 Million ≈ $-159.92 Million |
-0.125x | +32.44% |
| 2020-12-31 | €815.59 Million ≈ $953.51 Million |
€-151.09 Million ≈ $-176.64 Million |
-0.185x | -130.25% |
| 2019-12-31 | €372.30 Million ≈ $435.26 Million |
€-29.95 Million ≈ $-35.02 Million |
-0.080x | -112.90% |
| 2018-12-31 | €493.30 Million ≈ $576.72 Million |
€307.66 Million ≈ $359.69 Million |
0.624x | +566.40% |
| 2017-12-31 | €228.32 Million ≈ $266.93 Million |
€21.37 Million ≈ $24.98 Million |
0.094x | -48.24% |
| 2016-12-31 | €184.02 Million ≈ $215.14 Million |
€33.27 Million ≈ $38.90 Million |
0.181x | -- |
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Scien… Read more